PLASMINOGEN-ACTIVATOR INHIBITOR (PAI-1) IN PLASMA AND PLATELETS
PLASMINOGEN-ACTIVATOR INHIBITOR (PAI-1) IN PLASMA AND PLATELETS
复制标题
血浆和血小板中的纤溶酶原激活物抑制剂（PAI-1）
DOI：
10.1111/j.1365-2141.1988.tb02490.x
复制
发表时间：
1988-11-01
影响因子：
6.5
通讯作者：
MACGREGOR, IR
中科院分区：
文献类型：
--
作者：
BOOTH, NA;SIMPSON, AJ;MACGREGOR, IR
研究了派-1在正常人和血小板异常患者血浆和血小板中的分布。使用能够测量血浆中1.5ng/ml的派-1的ELISA和t-PA抑制的功能测定来测定无血小板血浆（PFP）、其中血小板溶解的富血小板血浆（PRP）和血清。正常PFP的派-1浓度为21.0 ± 0.01。7.2 ng/ml（平均值±）标准差（SD）为282.6 ± 0.01。68.0和270.3 . ±-。71.9 ng/ml。 PRP中派-1的浓度与血小板计数成正比，其相关系数为0.67 ± 0.99。0.18 ng/106血小板。血小板减少症患者PFP中派-1浓度接近正常，血清或PRP中极低浓度反映了血小板计数。患有灰色血小板综合征的患者显示出可比较的模式，证实派-1发生在血小板中。颗粒并表明血浆中派-1浓度不依赖于派-1的血小板库。正常PFP对t-PA的中位抑制活性分别为1.6、8.7和8.3单位/ml。PRP和血清。PFP中的派-1具有比血小板派-1高约5倍的中位比活性（单位/mg派-1）。血浆和血小板代表派-1的两个不同的池，这两者都应该在循环派-1和血栓性疾病之间的关系的研究中考虑。
The distribution of PAI-1 in the plasma and platelets of normal individuals and of patients with platelet abnormalities was studied. An ELISA, capable of measuring PAI-1 in plasma at 1.5 ng/ml, and a functional assay of t-PA inhibition were used to assay platelet-free plasma (PFP), platelet-rich plasma in which the platelets were lysed (PRP) and serum. The PAI-1 concentration of normal PFP was 21.0 .+-. 7.2 ng/ml (mean .+-. SD) and those of PRP and serum were 282.6 .+-. 68.0 and 270.3 .+-. 71.9 ng/ml. The concentration of PAI-1 in PRP was proportional to the platelet count with 0.67 .+-. 0.18 ng/106 platelets. Patients with thrombocytopenia had approximately normal PAI-1 concentrations in PFP, the extremely low concentrations in serum or PRP reflected the platelet count. A patient with grey platelet syndrome showed a comparable pattern, confirming that PAI-1 occurs in the platelet .chi.-granules and indicating that the plasma concentration of PAI-1 is independent of the platelet pool of PAI-1. The median inhibitory activities towards t-PA were 1.6, 8.7 and 8.3 units/ml in normal PFP. PRP and serum respectively. PAI-1 in PFP had a median specific activity (units/mg PAI-1) about 5-fold higher than platelet PAI-1. Plasma and platelets represent two distinct pools of PAI-1, both of which should be considered in studies on the relationship between circulating PAI-1 and thrombotic disease.